ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs
A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in patients with acute or acute-on-chronic respiratory acidosis (pH = 7.25-7.35). (1A) NIV should be attempted in patients with acute exacerbation...
Saved in:
Published in | Indian journal of critical care medicine Vol. 24; no. Suppl 1; pp. S61 - S81 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
India
Jaypee Brothers Medical Publishers
01.01.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in patients with acute or acute-on-chronic respiratory acidosis (pH = 7.25-7.35). (1A) NIV should be attempted in patients with acute exacerbation of COPD (pH <7.25 & PaCO2 ≥ 45) before initiating invasive mechanical ventilation (IMV) except in patients requiring immediate intubation. (2A). Lower the pH higher the chance of failure of NIV. (2B) NIV should not to be used routinely in normo- or mildly hyper-capneic patients with acute exacerbation of COPD, without acidosis (pH > 7.35). (2B) A2. NIV in ARF due to Chest wall deformities/Neuromuscular diseases: Recommendations: NIV may be used in patients of ARF due to chest wall deformity/Neuromuscular diseases. (PaCO2 ≥ 45) (UPP) A3. NIV in ARF due to Obesity hypoventilation syndrome (OHS): Recommendations: NIV may be used in AHRF in OHS patients when they present with acute hypercapnic or acute on chronic respiratory failure (pH 45). (3B) NIV/CPAP may be used in obese, hypercapnic patients with OHS and/or right heart failure in the absence of acidosis. (UPP) B.
B1. NIV in Acute Cardiogenic Pulmonary Oedema: Recommendations: NIV is recommended in hospital patients with ARF, due to Cardiogenic pulmonary edema. (1A). NIV should be used in patients with acute heart failure/ cardiogenic pulmonary edema, right from emergency department itself. (1B) Both CPAP and BiPAP modes are safe and effective in patients with cardiogenic pulmonary edema. (1A). However, BPAP (NIV-PS) should be preferred in cardiogenic pulmonary edema with hypercapnia. (3A) B2. NIV in acute hypoxemic respiratory failure: Recommendations: NIV may be used over conventional oxygen therapy in mild early acute hypoxemic respiratory failure (P/F ratio <300 and >200 mmHg), under close supervision. (2B) We strongly recommend against a trial of NIV in patients with acute hypoxemic failure with P/F ratio <150. (2A) B3. NIV in ARF due to Chest Trauma: Recommendations: NIV may be used in traumatic flail chest along with adequate pain relief. (3B) B4. NIV in Immunocompromised Host: Recommendations: In Immunocompromised patients with early ARF, we may consider NIV over conventional oxygen. (2B). B5. NIV in Palliative Care: Recommendations: We strongly recommend use of NIV for reducing dyspnea in palliative care setting. (2A) B6. NIV in post-operative cases: Recommendations: NIV should be used in patients with post-operative acute respiratory failure. (2A) B6a. NIV in abdominal surgery: Recommendations: NIV may be used in patients with ARF following abdominal surgeries. (2A) B6b. NIV in bariatric surgery: Recommendations: NIV may be used in post-bariatric surgery patients with pre-existent OSA or OHS. (3A) B6c. NIV in Thoracic surgery: Recommendations: In cardiothoracic surgeries, use of NIV is recommended post operatively for acute respiratory failure to improve oxygenation and reduce chance of reintubation. (2A) NIV should not be used in patients undergoing esophageal surgery. (UPP) B6d. NIV in post lung transplant: Recommendations: NIV may be used for shortening weaning time and to avoid re-intubation following lung transplantation. (2B) B7. NIV during Procedures (ETI/Bronchoscopy/TEE/Endoscopy): Recommendations: NIV may be used for pre-oxygenation before intubation. (2B) NIV with appropriate interface may be used in patients of ARF during Bronchoscopy/Endoscopy to improve oxygenation. (3B) B8. NIV in Viral Pneumonitis ARDS: Recommendations: NIV cannot be considered as a treatment of choice for patients with acute respiratory failure with H1N1 pneumonia. However, it may be reasonable to use NIV in selected patients with single organ involvement, in a strictly controlled environment with close monitoring. (2B) B9. NIV and Acute exacerbation of Pulmonary Tuberculosis: Recommendations: Careful use of NIV in patients with acute Tuberculosis may be considered, with effective infection control precautions to prevent air-borne transmission. (3B) B10. NIV after planned extubation in high risk patients: Recommendation: We recommend that NIV may be used to wean high risk patients from invasive mechanical ventilation as it reduces re-intubation rate. (2B) B11. NIV for respiratory distress post extubation: Recommendations: We recommend that NIV therapy should not be used to manage respiratory distress post-extubation in high risk patients. (2B) C.
Recommendation: Choice of mode should be mainly decided by factors like disease etiology and severity, the breathing effort by the patient and the operator familiarity and experience. (UPP) We suggest using flow trigger over pressure triggering in assisted modes, as it provides better patient ventilator synchrony. Especially in COPD patients, flow triggering has been found to benefit auto PEEP. (3B) D.
D1. Sedation: Recommendations: A non-pharmacological approach to calm the patient (Reassuring the patient, proper environment) should always be tried before administrating sedatives. (UPP) In patients on NIV, sedation may be used with extremely close monitoring and only in an ICU setting with lookout for signs of NIV failure. (UPP) E.
Recommendations: We recommend that portable bilevel ventilators or specifically designed ICU ventilators with non-invasive mode should be used for delivering Non-invasive ventilation in critically ill patients. (UPP) Both critical care ventilators with leak compensation and bi-level ventilators have been equally effective in decreasing the WOB, RR, and PaCO2. (3B) Currently, Oronasal mask is the most preferred interface for non-invasive ventilation for acute respiratory failure. (3B) F.
Recommendations: We recommend that weaning from NIV may be done by a standardized protocol driven approach of the unit. (2B)
Chawla R, Dixit SB, Zirpe KG, Chaudhry D, Khilnani GC, Mehta Y, et al. ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs. Indian J Crit Care Med 2020;24(Suppl 1):S61-S81. |
---|---|
AbstractList | A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in patients with acute or acute-on-chronic respiratory acidosis (pH = 7.25-7.35). (1A) NIV should be attempted in patients with acute exacerbation of COPD (pH <7.25 & PaCO2 ≥ 45) before initiating invasive mechanical ventilation (IMV) except in patients requiring immediate intubation. (2A). Lower the pH higher the chance of failure of NIV. (2B) NIV should not to be used routinely in normo- or mildly hyper-capneic patients with acute exacerbation of COPD, without acidosis (pH > 7.35). (2B) A2. NIV in ARF due to Chest wall deformities/Neuromuscular diseases: Recommendations: NIV may be used in patients of ARF due to chest wall deformity/Neuromuscular diseases. (PaCO2 ≥ 45) (UPP) A3. NIV in ARF due to Obesity hypoventilation syndrome (OHS): Recommendations: NIV may be used in AHRF in OHS patients when they present with acute hypercapnic or acute on chronic respiratory failure (pH 45). (3B) NIV/CPAP may be used in obese, hypercapnic patients with OHS and/or right heart failure in the absence of acidosis. (UPP) B. NIV IN ACUTE HYPOXEMIC RESPIRATORY FAILURE: B1. NIV in Acute Cardiogenic Pulmonary Oedema: Recommendations: NIV is recommended in hospital patients with ARF, due to Cardiogenic pulmonary edema. (1A). NIV should be used in patients with acute heart failure/ cardiogenic pulmonary edema, right from emergency department itself. (1B) Both CPAP and BiPAP modes are safe and effective in patients with cardiogenic pulmonary edema. (1A). However, BPAP (NIV-PS) should be preferred in cardiogenic pulmonary edema with hypercapnia. (3A) B2. NIV in acute hypoxemic respiratory failure: Recommendations: NIV may be used over conventional oxygen therapy in mild early acute hypoxemic respiratory failure (P/F ratio <300 and >200 mmHg), under close supervision. (2B) We strongly recommend against a trial of NIV in patients with acute hypoxemic failure with P/F ratio <150. (2A) B3. NIV in ARF due to Chest Trauma: Recommendations: NIV may be used in traumatic flail chest along with adequate pain relief. (3B) B4. NIV in Immunocompromised Host: Recommendations: In Immunocompromised patients with early ARF, we may consider NIV over conventional oxygen. (2B). B5. NIV in Palliative Care: Recommendations: We strongly recommend use of NIV for reducing dyspnea in palliative care setting. (2A) B6. NIV in post-operative cases: Recommendations: NIV should be used in patients with post-operative acute respiratory failure. (2A) B6a. NIV in abdominal surgery: Recommendations: NIV may be used in patients with ARF following abdominal surgeries. (2A) B6b. NIV in bariatric surgery: Recommendations: NIV may be used in post-bariatric surgery patients with pre-existent OSA or OHS. (3A) B6c. NIV in Thoracic surgery: Recommendations: In cardiothoracic surgeries, use of NIV is recommended post operatively for acute respiratory failure to improve oxygenation and reduce chance of reintubation. (2A) NIV should not be used in patients undergoing esophageal surgery. (UPP) B6d. NIV in post lung transplant: Recommendations: NIV may be used for shortening weaning time and to avoid re-intubation following lung transplantation. (2B) B7. NIV during Procedures (ETI/Bronchoscopy/TEE/Endoscopy): Recommendations: NIV may be used for pre-oxygenation before intubation. (2B) NIV with appropriate interface may be used in patients of ARF during Bronchoscopy/Endoscopy to improve oxygenation. (3B) B8. NIV in Viral Pneumonitis ARDS: Recommendations: NIV cannot be considered as a treatment of choice for patients with acute respiratory failure with H1N1 pneumonia. However, it may be reasonable to use NIV in selected patients with single organ involvement, in a strictly controlled environment with close monitoring. (2B) B9. NIV and Acute exacerbation of Pulmonary Tuberculosis: Recommendations: Careful use of NIV in patients with acute Tuberculosis may be considered, with effective infection control precautions to prevent air-borne transmission. (3B) B10. NIV after planned extubation in high risk patients: Recommendation: We recommend that NIV may be used to wean high risk patients from invasive mechanical ventilation as it reduces re-intubation rate. (2B) B11. NIV for respiratory distress post extubation: Recommendations: We recommend that NIV therapy should not be used to manage respiratory distress post-extubation in high risk patients. (2B) C. APPLICATION OF NIV: Recommendation: Choice of mode should be mainly decided by factors like disease etiology and severity, the breathing effort by the patient and the operator familiarity and experience. (UPP) We suggest using flow trigger over pressure triggering in assisted modes, as it provides better patient ventilator synchrony. Especially in COPD patients, flow triggering has been found to benefit auto PEEP. (3B) D. MANAGEMENT OF PATIENT ON NIV: D1. Sedation: Recommendations: A non-pharmacological approach to calm the patient (Reassuring the patient, proper environment) should always be tried before administrating sedatives. (UPP) In patients on NIV, sedation may be used with extremely close monitoring and only in an ICU setting with lookout for signs of NIV failure. (UPP) E. EQUIPMENT: Recommendations: We recommend that portable bilevel ventilators or specifically designed ICU ventilators with non-invasive mode should be used for delivering Non–invasive ventilation in critically ill patients. (UPP) Both critical care ventilators with leak compensation and bi-level ventilators have been equally effective in decreasing the WOB, RR, and PaCO2. (3B) Currently, Oronasal mask is the most preferred interface for non-invasive ventilation for acute respiratory failure. (3B) F. WEANING: Recommendations: We recommend that weaning from NIV may be done by a standardized protocol driven approach of the unit. (2B)
How to cite this article:
Chawla R, Dixit SB, Zirpe KG, Chaudhry D, Khilnani GC, Mehta Y, et al. ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs. Indian J Crit Care Med 2020;24(Suppl 1):S61–S81. A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in patients with acute or acute-on-chronic respiratory acidosis (pH = 7.25-7.35). (1A) NIV should be attempted in patients with acute exacerbation of COPD (pH <7.25 & PaCO2 ≥ 45) before initiating invasive mechanical ventilation (IMV) except in patients requiring immediate intubation. (2A). Lower the pH higher the chance of failure of NIV. (2B) NIV should not to be used routinely in normo- or mildly hyper-capneic patients with acute exacerbation of COPD, without acidosis (pH > 7.35). (2B) A2. NIV in ARF due to Chest wall deformities/Neuromuscular diseases: Recommendations: NIV may be used in patients of ARF due to chest wall deformity/Neuromuscular diseases. (PaCO2 ≥ 45) (UPP) A3. NIV in ARF due to Obesity hypoventilation syndrome (OHS): Recommendations: NIV may be used in AHRF in OHS patients when they present with acute hypercapnic or acute on chronic respiratory failure (pH 45). (3B) NIV/CPAP may be used in obese, hypercapnic patients with OHS and/or right heart failure in the absence of acidosis. (UPP) B.A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in patients with acute or acute-on-chronic respiratory acidosis (pH = 7.25-7.35). (1A) NIV should be attempted in patients with acute exacerbation of COPD (pH <7.25 & PaCO2 ≥ 45) before initiating invasive mechanical ventilation (IMV) except in patients requiring immediate intubation. (2A). Lower the pH higher the chance of failure of NIV. (2B) NIV should not to be used routinely in normo- or mildly hyper-capneic patients with acute exacerbation of COPD, without acidosis (pH > 7.35). (2B) A2. NIV in ARF due to Chest wall deformities/Neuromuscular diseases: Recommendations: NIV may be used in patients of ARF due to chest wall deformity/Neuromuscular diseases. (PaCO2 ≥ 45) (UPP) A3. NIV in ARF due to Obesity hypoventilation syndrome (OHS): Recommendations: NIV may be used in AHRF in OHS patients when they present with acute hypercapnic or acute on chronic respiratory failure (pH 45). (3B) NIV/CPAP may be used in obese, hypercapnic patients with OHS and/or right heart failure in the absence of acidosis. (UPP) B.B1. NIV in Acute Cardiogenic Pulmonary Oedema: Recommendations: NIV is recommended in hospital patients with ARF, due to Cardiogenic pulmonary edema. (1A). NIV should be used in patients with acute heart failure/ cardiogenic pulmonary edema, right from emergency department itself. (1B) Both CPAP and BiPAP modes are safe and effective in patients with cardiogenic pulmonary edema. (1A). However, BPAP (NIV-PS) should be preferred in cardiogenic pulmonary edema with hypercapnia. (3A) B2. NIV in acute hypoxemic respiratory failure: Recommendations: NIV may be used over conventional oxygen therapy in mild early acute hypoxemic respiratory failure (P/F ratio <300 and >200 mmHg), under close supervision. (2B) We strongly recommend against a trial of NIV in patients with acute hypoxemic failure with P/F ratio <150. (2A) B3. NIV in ARF due to Chest Trauma: Recommendations: NIV may be used in traumatic flail chest along with adequate pain relief. (3B) B4. NIV in Immunocompromised Host: Recommendations: In Immunocompromised patients with early ARF, we may consider NIV over conventional oxygen. (2B). B5. NIV in Palliative Care: Recommendations: We strongly recommend use of NIV for reducing dyspnea in palliative care setting. (2A) B6. NIV in post-operative cases: Recommendations: NIV should be used in patients with post-operative acute respiratory failure. (2A) B6a. NIV in abdominal surgery: Recommendations: NIV may be used in patients with ARF following abdominal surgeries. (2A) B6b. NIV in bariatric surgery: Recommendations: NIV may be used in post-bariatric surgery patients with pre-existent OSA or OHS. (3A) B6c. NIV in Thoracic surgery: Recommendations: In cardiothoracic surgeries, use of NIV is recommended post operatively for acute respiratory failure to improve oxygenation and reduce chance of reintubation. (2A) NIV should not be used in patients undergoing esophageal surgery. (UPP) B6d. NIV in post lung transplant: Recommendations: NIV may be used for shortening weaning time and to avoid re-intubation following lung transplantation. (2B) B7. NIV during Procedures (ETI/Bronchoscopy/TEE/Endoscopy): Recommendations: NIV may be used for pre-oxygenation before intubation. (2B) NIV with appropriate interface may be used in patients of ARF during Bronchoscopy/Endoscopy to improve oxygenation. (3B) B8. NIV in Viral Pneumonitis ARDS: Recommendations: NIV cannot be considered as a treatment of choice for patients with acute respiratory failure with H1N1 pneumonia. However, it may be reasonable to use NIV in selected patients with single organ involvement, in a strictly controlled environment with close monitoring. (2B) B9. NIV and Acute exacerbation of Pulmonary Tuberculosis: Recommendations: Careful use of NIV in patients with acute Tuberculosis may be considered, with effective infection control precautions to prevent air-borne transmission. (3B) B10. NIV after planned extubation in high risk patients: Recommendation: We recommend that NIV may be used to wean high risk patients from invasive mechanical ventilation as it reduces re-intubation rate. (2B) B11. NIV for respiratory distress post extubation: Recommendations: We recommend that NIV therapy should not be used to manage respiratory distress post-extubation in high risk patients. (2B) C.NIV IN ACUTE HYPOXEMIC RESPIRATORY FAILUREB1. NIV in Acute Cardiogenic Pulmonary Oedema: Recommendations: NIV is recommended in hospital patients with ARF, due to Cardiogenic pulmonary edema. (1A). NIV should be used in patients with acute heart failure/ cardiogenic pulmonary edema, right from emergency department itself. (1B) Both CPAP and BiPAP modes are safe and effective in patients with cardiogenic pulmonary edema. (1A). However, BPAP (NIV-PS) should be preferred in cardiogenic pulmonary edema with hypercapnia. (3A) B2. NIV in acute hypoxemic respiratory failure: Recommendations: NIV may be used over conventional oxygen therapy in mild early acute hypoxemic respiratory failure (P/F ratio <300 and >200 mmHg), under close supervision. (2B) We strongly recommend against a trial of NIV in patients with acute hypoxemic failure with P/F ratio <150. (2A) B3. NIV in ARF due to Chest Trauma: Recommendations: NIV may be used in traumatic flail chest along with adequate pain relief. (3B) B4. NIV in Immunocompromised Host: Recommendations: In Immunocompromised patients with early ARF, we may consider NIV over conventional oxygen. (2B). B5. NIV in Palliative Care: Recommendations: We strongly recommend use of NIV for reducing dyspnea in palliative care setting. (2A) B6. NIV in post-operative cases: Recommendations: NIV should be used in patients with post-operative acute respiratory failure. (2A) B6a. NIV in abdominal surgery: Recommendations: NIV may be used in patients with ARF following abdominal surgeries. (2A) B6b. NIV in bariatric surgery: Recommendations: NIV may be used in post-bariatric surgery patients with pre-existent OSA or OHS. (3A) B6c. NIV in Thoracic surgery: Recommendations: In cardiothoracic surgeries, use of NIV is recommended post operatively for acute respiratory failure to improve oxygenation and reduce chance of reintubation. (2A) NIV should not be used in patients undergoing esophageal surgery. (UPP) B6d. NIV in post lung transplant: Recommendations: NIV may be used for shortening weaning time and to avoid re-intubation following lung transplantation. (2B) B7. NIV during Procedures (ETI/Bronchoscopy/TEE/Endoscopy): Recommendations: NIV may be used for pre-oxygenation before intubation. (2B) NIV with appropriate interface may be used in patients of ARF during Bronchoscopy/Endoscopy to improve oxygenation. (3B) B8. NIV in Viral Pneumonitis ARDS: Recommendations: NIV cannot be considered as a treatment of choice for patients with acute respiratory failure with H1N1 pneumonia. However, it may be reasonable to use NIV in selected patients with single organ involvement, in a strictly controlled environment with close monitoring. (2B) B9. NIV and Acute exacerbation of Pulmonary Tuberculosis: Recommendations: Careful use of NIV in patients with acute Tuberculosis may be considered, with effective infection control precautions to prevent air-borne transmission. (3B) B10. NIV after planned extubation in high risk patients: Recommendation: We recommend that NIV may be used to wean high risk patients from invasive mechanical ventilation as it reduces re-intubation rate. (2B) B11. NIV for respiratory distress post extubation: Recommendations: We recommend that NIV therapy should not be used to manage respiratory distress post-extubation in high risk patients. (2B) C.Recommendation: Choice of mode should be mainly decided by factors like disease etiology and severity, the breathing effort by the patient and the operator familiarity and experience. (UPP) We suggest using flow trigger over pressure triggering in assisted modes, as it provides better patient ventilator synchrony. Especially in COPD patients, flow triggering has been found to benefit auto PEEP. (3B) D.APPLICATION OF NIVRecommendation: Choice of mode should be mainly decided by factors like disease etiology and severity, the breathing effort by the patient and the operator familiarity and experience. (UPP) We suggest using flow trigger over pressure triggering in assisted modes, as it provides better patient ventilator synchrony. Especially in COPD patients, flow triggering has been found to benefit auto PEEP. (3B) D.D1. Sedation: Recommendations: A non-pharmacological approach to calm the patient (Reassuring the patient, proper environment) should always be tried before administrating sedatives. (UPP) In patien A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in patients with acute or acute-on-chronic respiratory acidosis (pH = 7.25-7.35). (1A) NIV should be attempted in patients with acute exacerbation of COPD (pH <7.25 & PaCO2 ≥ 45) before initiating invasive mechanical ventilation (IMV) except in patients requiring immediate intubation. (2A). Lower the pH higher the chance of failure of NIV. (2B) NIV should not to be used routinely in normo- or mildly hyper-capneic patients with acute exacerbation of COPD, without acidosis (pH > 7.35). (2B) A2. NIV in ARF due to Chest wall deformities/Neuromuscular diseases: Recommendations: NIV may be used in patients of ARF due to chest wall deformity/Neuromuscular diseases. (PaCO2 ≥ 45) (UPP) A3. NIV in ARF due to Obesity hypoventilation syndrome (OHS): Recommendations: NIV may be used in AHRF in OHS patients when they present with acute hypercapnic or acute on chronic respiratory failure (pH 45). (3B) NIV/CPAP may be used in obese, hypercapnic patients with OHS and/or right heart failure in the absence of acidosis. (UPP) B. B1. NIV in Acute Cardiogenic Pulmonary Oedema: Recommendations: NIV is recommended in hospital patients with ARF, due to Cardiogenic pulmonary edema. (1A). NIV should be used in patients with acute heart failure/ cardiogenic pulmonary edema, right from emergency department itself. (1B) Both CPAP and BiPAP modes are safe and effective in patients with cardiogenic pulmonary edema. (1A). However, BPAP (NIV-PS) should be preferred in cardiogenic pulmonary edema with hypercapnia. (3A) B2. NIV in acute hypoxemic respiratory failure: Recommendations: NIV may be used over conventional oxygen therapy in mild early acute hypoxemic respiratory failure (P/F ratio <300 and >200 mmHg), under close supervision. (2B) We strongly recommend against a trial of NIV in patients with acute hypoxemic failure with P/F ratio <150. (2A) B3. NIV in ARF due to Chest Trauma: Recommendations: NIV may be used in traumatic flail chest along with adequate pain relief. (3B) B4. NIV in Immunocompromised Host: Recommendations: In Immunocompromised patients with early ARF, we may consider NIV over conventional oxygen. (2B). B5. NIV in Palliative Care: Recommendations: We strongly recommend use of NIV for reducing dyspnea in palliative care setting. (2A) B6. NIV in post-operative cases: Recommendations: NIV should be used in patients with post-operative acute respiratory failure. (2A) B6a. NIV in abdominal surgery: Recommendations: NIV may be used in patients with ARF following abdominal surgeries. (2A) B6b. NIV in bariatric surgery: Recommendations: NIV may be used in post-bariatric surgery patients with pre-existent OSA or OHS. (3A) B6c. NIV in Thoracic surgery: Recommendations: In cardiothoracic surgeries, use of NIV is recommended post operatively for acute respiratory failure to improve oxygenation and reduce chance of reintubation. (2A) NIV should not be used in patients undergoing esophageal surgery. (UPP) B6d. NIV in post lung transplant: Recommendations: NIV may be used for shortening weaning time and to avoid re-intubation following lung transplantation. (2B) B7. NIV during Procedures (ETI/Bronchoscopy/TEE/Endoscopy): Recommendations: NIV may be used for pre-oxygenation before intubation. (2B) NIV with appropriate interface may be used in patients of ARF during Bronchoscopy/Endoscopy to improve oxygenation. (3B) B8. NIV in Viral Pneumonitis ARDS: Recommendations: NIV cannot be considered as a treatment of choice for patients with acute respiratory failure with H1N1 pneumonia. However, it may be reasonable to use NIV in selected patients with single organ involvement, in a strictly controlled environment with close monitoring. (2B) B9. NIV and Acute exacerbation of Pulmonary Tuberculosis: Recommendations: Careful use of NIV in patients with acute Tuberculosis may be considered, with effective infection control precautions to prevent air-borne transmission. (3B) B10. NIV after planned extubation in high risk patients: Recommendation: We recommend that NIV may be used to wean high risk patients from invasive mechanical ventilation as it reduces re-intubation rate. (2B) B11. NIV for respiratory distress post extubation: Recommendations: We recommend that NIV therapy should not be used to manage respiratory distress post-extubation in high risk patients. (2B) C. Recommendation: Choice of mode should be mainly decided by factors like disease etiology and severity, the breathing effort by the patient and the operator familiarity and experience. (UPP) We suggest using flow trigger over pressure triggering in assisted modes, as it provides better patient ventilator synchrony. Especially in COPD patients, flow triggering has been found to benefit auto PEEP. (3B) D. D1. Sedation: Recommendations: A non-pharmacological approach to calm the patient (Reassuring the patient, proper environment) should always be tried before administrating sedatives. (UPP) In patients on NIV, sedation may be used with extremely close monitoring and only in an ICU setting with lookout for signs of NIV failure. (UPP) E. Recommendations: We recommend that portable bilevel ventilators or specifically designed ICU ventilators with non-invasive mode should be used for delivering Non-invasive ventilation in critically ill patients. (UPP) Both critical care ventilators with leak compensation and bi-level ventilators have been equally effective in decreasing the WOB, RR, and PaCO2. (3B) Currently, Oronasal mask is the most preferred interface for non-invasive ventilation for acute respiratory failure. (3B) F. Recommendations: We recommend that weaning from NIV may be done by a standardized protocol driven approach of the unit. (2B) Chawla R, Dixit SB, Zirpe KG, Chaudhry D, Khilnani GC, Mehta Y, et al. ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs. Indian J Crit Care Med 2020;24(Suppl 1):S61-S81. |
Author | Marwah, Vikas Chawla, Rajesh Chaudhry, Dhruva Prayag, Shirish Sehgal, Inder Khatib, Khalid Ismail Chanchalani, Gunjan Kulkarni, Atul Prabhakar Khilnani, G C Zirpe, Kapil Gangadhar Govil, Deepak Mehta, Yatin Dixit, Subhal B Samavedam, Srinivas Gupta, Sachin Ramasubban, Suresh Mishra, Rajesh C Dobariya, Jayesh Jog, Sameer Arvind Jagiasi, Bharat G |
AuthorAffiliation | 20 Department of Division of Critical Care Medicine, Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India, Phone: 91-9869077526, e-mail: kaivalyaak@yahoo.co.in 11 Department of Critical Care, Virinchi Hospital, Hyderabad, Telangana, India, Phone: 9866343632, e-mail: srinivas3271@gmail.com 4 Department of Pulmonary and Critical Care Medicine, PGIMS, Rohtak, Haryana, India, Phone: +91-9991101616, e-mail: dhruvachaudhry@yahoo.co.in 10 Department of Critical Care, Saneejivini Hospital, Vastrapur, Ahmedabad, Gujarat, India, Phone: +91-9924231500, e-mail: mishr.c@gmail.com 1 Department of Respiratory and Critical Care Medicine, Indraprastha Apollo Hospitals, New Delhi, India, Phone: +91-9810033395, e-mail: drchawla@hotmail.com 2 Department of Critical Care, Sanjeevan & MJM Hospital, Pune, Maharashtra, India, Phone: +91-9822050240, 020-25531539 / 25539538, e-mail: subhaldixit@gmail.com 9 Department of Critical Care Med |
AuthorAffiliation_xml | – name: 3 Department of Neurotrauma Unit, Ruby Hall Clinic, Pune, Maharashtra, India, Phone: +91-9822844212, e-mail: kapilzirpe@gmail.com – name: 4 Department of Pulmonary and Critical Care Medicine, PGIMS, Rohtak, Haryana, India, Phone: +91-9991101616, e-mail: dhruvachaudhry@yahoo.co.in – name: 11 Department of Critical Care, Virinchi Hospital, Hyderabad, Telangana, India, Phone: 9866343632, e-mail: srinivas3271@gmail.com – name: 13 Department of Critical Care Medicine, Narayana Superspeciality Hospital, Gurugram, Haryana, India, Phone: +91-9873240734, e-mail: dr_sachin78@yahoo.co.in – name: 1 Department of Respiratory and Critical Care Medicine, Indraprastha Apollo Hospitals, New Delhi, India, Phone: +91-9810033395, e-mail: drchawla@hotmail.com – name: 18 Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India, Phone: 0172-2756823, e-mail: inderpgi@outlook.com – name: 8 Department of Critical Care, Reliance Hospital, Navi Mumbai, Maharashtra, India, Phone: 9766363200, e-mail: bharatjigiasi@yahoo.com – name: 17 Department of Pulmonary, Critical Care and Sleep Medicine, Military Hospital (CTC), Pune, Maharashtra, India, Phone: 9560503335, e-mail: docvikasmarwah@gmail.com – name: 2 Department of Critical Care, Sanjeevan & MJM Hospital, Pune, Maharashtra, India, Phone: +91-9822050240, 020-25531539 / 25539538, e-mail: subhaldixit@gmail.com – name: 7 Department of Medicine, SKN Medical College, Pune, Maharashtra, India, Phone: +91-9822091745, e-mail: drkhatibkhalid@gmail.com – name: 15 Department of Critical Care, Apollo Gleneagles Hospital Limited, Kolkata, India, Phone: +91-33-23203040, e-mail: drsuresh@hotmail.com – name: 16 Department of critical care, Synergy Hospital Rajkot, Rajkot, Gujarat, India, Phone: +91-9825043590, e-mail: jayeshdobariya@yahoo.co.in – name: 12 Department of Critical Care, Medanta Hospital, The Medicity, Gurugram, Haryana, India, Phone: 91-11-26692531, e-mail: drdeepak_govil@yahoo.co.in – name: 20 Department of Division of Critical Care Medicine, Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India, Phone: 91-9869077526, e-mail: kaivalyaak@yahoo.co.in – name: 5 Department of PSRI Institute of Pulmonary, Critical Care and Sleep Medicine, PSRI Hospital, New Delhi, India, Phone: +91-9810 353 696, e-mail: gckhil@gmail.com – name: 10 Department of Critical Care, Saneejivini Hospital, Vastrapur, Ahmedabad, Gujarat, India, Phone: +91-9924231500, e-mail: mishr.c@gmail.com – name: 9 Department of Critical Care Medicine, Bhatia Hospital, Mumbai, Maharashtra, India, Phone: 9757169559, e-mail: gunj80@gmail.com – name: 19 Department of Critical Care, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India, Phone: 91-9823018178, 91-9823018178, e-mail: drjogs@gmail.com – name: 6 Department of Medanta Institute of Critical Care and Anesthesiology, Medanta The Medicity, Sector-38, Gurgaon-122001, Haryana, India, Phone: + 91 124 4141414 Extn. 3335, e-mail: yatinmehta@hotmail.com – name: 14 Department of Critical Care, Prayag Hospital, Pune, Maharashtra, India, Phone: 91-20-25534448, e-mail: shirishprayag@gmail.com |
Author_xml | – sequence: 1 givenname: Rajesh surname: Chawla fullname: Chawla, Rajesh email: drchawla@hotmail.com organization: Department of Respiratory and Critical Care Medicine, Indraprastha Apollo Hospitals, New Delhi, India, , e-mail: drchawla@hotmail.com – sequence: 2 givenname: Subhal B surname: Dixit fullname: Dixit, Subhal B email: subhaldixit@gmail.com organization: Department of Critical Care, Sanjeevan & MJM Hospital, Pune, Maharashtra, India, , 020-25531539 / 25539538, e-mail: subhaldixit@gmail.com – sequence: 3 givenname: Kapil Gangadhar surname: Zirpe fullname: Zirpe, Kapil Gangadhar email: kapilzirpe@gmail.com organization: Department of Neurotrauma Unit, Ruby Hall Clinic, Pune, Maharashtra, India, , e-mail: kapilzirpe@gmail.com – sequence: 4 givenname: Dhruva surname: Chaudhry fullname: Chaudhry, Dhruva email: dhruvachaudhry@yahoo.co.in organization: Department of Pulmonary and Critical Care Medicine, PGIMS, Rohtak, Haryana, India, , e-mail: dhruvachaudhry@yahoo.co.in – sequence: 5 givenname: G C surname: Khilnani fullname: Khilnani, G C email: gckhil@gmail.com organization: Department of PSRI Institute of Pulmonary, Critical Care and Sleep Medicine, PSRI Hospital, New Delhi, India, , e-mail: gckhil@gmail.com – sequence: 6 givenname: Yatin surname: Mehta fullname: Mehta, Yatin email: yatinmehta@hotmail.com organization: Department of Medanta Institute of Critical Care and Anesthesiology, Medanta The Medicity, Sector-38, Gurgaon-122001, Haryana, India, Extn. 3335, e-mail: yatinmehta@hotmail.com – sequence: 7 givenname: Khalid Ismail surname: Khatib fullname: Khatib, Khalid Ismail email: drkhatibkhalid@gmail.com organization: Department of Medicine, SKN Medical College, Pune, Maharashtra, India, , e-mail: drkhatibkhalid@gmail.com – sequence: 8 givenname: Bharat G surname: Jagiasi fullname: Jagiasi, Bharat G email: bharatjigiasi@yahoo.com organization: Department of Critical Care, Reliance Hospital, Navi Mumbai, Maharashtra, India, , e-mail: bharatjigiasi@yahoo.com – sequence: 9 givenname: Gunjan surname: Chanchalani fullname: Chanchalani, Gunjan email: gunj80@gmail.com organization: Department of Critical Care Medicine, Bhatia Hospital, Mumbai, Maharashtra, India, , e-mail: gunj80@gmail.com – sequence: 10 givenname: Rajesh C surname: Mishra fullname: Mishra, Rajesh C email: mishr.c@gmail.com organization: Department of Critical Care, Saneejivini Hospital, Vastrapur, Ahmedabad, Gujarat, India, , e-mail: mishr.c@gmail.com – sequence: 11 givenname: Srinivas surname: Samavedam fullname: Samavedam, Srinivas email: srinivas3271@gmail.com organization: Department of Critical Care, Virinchi Hospital, Hyderabad, Telangana, India, , e-mail: srinivas3271@gmail.com – sequence: 12 givenname: Deepak surname: Govil fullname: Govil, Deepak email: drdeepak_govil@yahoo.co.in organization: Department of Critical Care, Medanta Hospital, The Medicity, Gurugram, Haryana, India, , e-mail: drdeepak_govil@yahoo.co.in – sequence: 13 givenname: Sachin surname: Gupta fullname: Gupta, Sachin email: dr_sachin78@yahoo.co.in organization: Department of Critical Care Medicine, Narayana Superspeciality Hospital, Gurugram, Haryana, India, , e-mail: dr_sachin78@yahoo.co.in – sequence: 14 givenname: Shirish surname: Prayag fullname: Prayag, Shirish email: shirishprayag@gmail.com organization: Department of Critical Care, Prayag Hospital, Pune, Maharashtra, India, , e-mail: shirishprayag@gmail.com – sequence: 15 givenname: Suresh surname: Ramasubban fullname: Ramasubban, Suresh email: drsuresh@hotmail.com organization: Department of Critical Care, Apollo Gleneagles Hospital Limited, Kolkata, India, , e-mail: drsuresh@hotmail.com – sequence: 16 givenname: Jayesh surname: Dobariya fullname: Dobariya, Jayesh email: jayeshdobariya@yahoo.co.in organization: Department of critical care, Synergy Hospital Rajkot, Rajkot, Gujarat, India, , e-mail: jayeshdobariya@yahoo.co.in – sequence: 17 givenname: Vikas surname: Marwah fullname: Marwah, Vikas email: docvikasmarwah@gmail.com organization: Department of Pulmonary, Critical Care and Sleep Medicine, Military Hospital (CTC), Pune, Maharashtra, India, , e-mail: docvikasmarwah@gmail.com – sequence: 18 givenname: Inder surname: Sehgal fullname: Sehgal, Inder email: inderpgi@outlook.com organization: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India, , e-mail: inderpgi@outlook.com – sequence: 19 givenname: Sameer Arvind surname: Jog fullname: Jog, Sameer Arvind email: drjogs@gmail.com organization: Department of Critical Care, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India, , 91-9823018178, e-mail: drjogs@gmail.com – sequence: 20 givenname: Atul Prabhakar surname: Kulkarni fullname: Kulkarni, Atul Prabhakar email: kaivalyaak@yahoo.co.in organization: Department of Division of Critical Care Medicine, Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India, , e-mail: kaivalyaak@yahoo.co.in |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32205957$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkctu1DAUhi3Uik4Lr4C8ZGPwJY6dDVIV0WGkQiVgqu4sxzmmHmXsYCcj9e0JnbaC1Vn8l_NL3zk6iSkCQpjRD5JS-XE3kl2ac7RDIYxSxciaC6brV2jFmkYTIZu7E7SijeJEct6cofNSdpTyuuHsNToTnFPZSLVCbvOjbb_i9Rx6GEKEgn3KeLoHvC2Ak8ffUiQhHmwJB8C3EKcw2CmkiEPEl26eAH-HMoZsp5Qf8JUNw5zhUeznYcKbdlveoFO_LIW3T_cCba8-_2y_kOub9aa9vCZO1HIiXghnFXO9tE55qGRXead6pi3rKkY91dKChZ5yLXSlbF31jfVK9475ru-4uECfjr3j3O2hd8vYbAcz5rC3-cEkG8z_Sgz35lc6GLVUa6aWgvdPBTn9nqFMZh-Kg2GwEdJcDBea17Xkolqs-mh1OZWSwb-8YdT8ZWR2o3lmZB4ZmSOjJfru35kvwWco4g8kF5VM |
Cites_doi | 10.1016/j.rmed.2006.03.018 10.1007/s00134-017-4947-1 10.1136/bmj.c5462 10.1136/emj.2004.019786 10.1164/rccm.200509-1507OC 10.1136/emj.2009.089102 10.1016/S0140-6736(06)68506-1 10.1056/NEJM200102153440703 10.1056/NEJM199509283331301 10.1136/thorax.55.7.550 10.1016/j.jcrc.2008.08.007 10.1097/SLA.0b013e3181675829 10.1177/1751143715571698 10.4187/respcare.04619 10.1097/00000542-199808000-00013 10.1007/s00134-005-2823-x 10.1016/S0140-6736(00)47948-1 10.1136/pgmj.2004.031229 10.1016/S1470-2045(13)70009-3 10.1086/514711 10.1001/jama.2015.5213 10.1097/CCM.0000000000002361 10.1016/j.soard.2017.02.009 10.1186/s12873-018-0216-z 10.1186/cc3805 10.1164/rccm.201606-1306OC 10.1016/j.annfar.2009.04.012 10.1016/j.jcrc.2015.10.018 10.1503/cmaj.100071 10.1097/ALN.0b013e3181c5e5f2 10.1136/thx.52.3.249 10.1186/s13054-019-2575-6 10.1378/chest.09-1114 10.1378/chest.09-2517 10.5664/jcsm.6278 10.5005/jp-journals-10071-23219 10.1007/s00134-008-0998-7 10.5152/TurkThoracJ.2017.17036 10.1007/s11695-011-0381-6 10.1111/j.1469-0691.2012.03797.x 10.1177/0885066619844713 10.5005/jp-journals-10071-23101 10.1183/09031936.01.17202590 10.1164/ajrccm.164.7.2101089 10.1164/rccm.201206-1101OC 10.1007/s12630-011-9497-3 10.1111/j.1742-1241.2002.tb11202.x 10.1007/s00134-015-4087-4 10.1186/cc8044 10.1002/14651858.CD005351.pub3 10.1378/chest.97.4.943 10.1097/CCM.0000000000002818 10.1001/jama.2016.2706 10.1378/chest.128.4.2688 10.1001/jama.284.18.2361 10.1186/s13054-016-1586-9 10.4187/respcare.05481 10.2169/internalmedicine.49.3749 10.1378/chest.122.5.1857 10.1186/1471-2466-13-12 10.1136/thx.2008.102947 10.5005/ijccm-17-S1-42 10.1016/j.rmed.2012.03.009 10.1136/thx.47.1.34 10.1164/ajrccm.161.3.9808143 10.1378/chest.104.3.770 10.1111/imj.13632 10.1136/thoraxjnl-2015-208209 10.1007/978-3-642-11365-9_36 10.1097/MD.0000000000004734 10.1001/jama.294.24.3124 10.1016/j.jcrc.2017.01.007 10.1001/jama.290.22.2985 10.1016/j.soard.2008.05.003 10.1056/NEJMoa0707992 10.1016/0002-9343(93)90060-3 10.1007/s11695-009-9928-1 10.1378/chest.09-0360 10.1186/s12890-016-0289-y 10.4187/respcare.01775 10.1164/ajrccm/142.3.523 10.1378/chest.127.3.952 10.1183/09031936.02.00287402 10.1016/j.annemergmed.2006.10.024 10.1002/14651858.CD004104.pub3 10.1164/ajrccm.157.1.96-12052 10.1080/17434440.2016.1218759 10.1016/j.jjcc.2016.05.015 10.1053/jcan.2000.9488 10.1007/s11695-007-9079-1 10.1136/thx.56.9.708 10.1164/ajrccm.164.9.2011119 10.1378/chest.114.6.1636 10.1016/S0140-6736(00)02323-0 10.1016/j.jcrc.2016.12.023 10.1016/0140-6736(93)90696-E 10.1136/thx.2010.142661 10.1183/09031936.96.09061240 10.1186/s12890-015-0139-3 10.1378/chest.116.2.521 10.2147/COPD.S3454 10.1007/s00134-011-2375-1 10.1183/13993003.02426-2016 10.1590/S1413-35552010005000023 10.7326/0003-4819-12-6-754 10.1186/cc10328 10.1097/ALN.0b013e31821811ba 10.1164/ajrccm.163.1.ats1000 10.1183/09031936.00.15109800 10.1016/S0025-7753(03)73798-1 10.1007/s00134-001-1114-4 10.1001/jama.2015.12402 10.1177/000313480807400914 10.1136/thx.51.10.1048 10.1186/s13054-018-2079-9 10.1136/thx.2010.153114 10.1164/ajrccm.151.6.7767523 10.1186/cc13103 10.4103/0970-2113.68308 10.1016/j.transproceed.2009.02.048 10.1097/CCM.0000000000001379 10.7326/0003-4819-138-11-200306030-00007 10.1001/jama.2009.1496 10.1007/s00134-002-1478-0 10.1136/thorax.57.3.192 10.1007/BF02968110 10.1007/s00134-009-1717-8 10.1002/14651858.CD004104.pub4 10.1378/chest.113.5.1339 10.1016/j.medine.2019.11.007 10.1093/ageing/afr003 10.1001/jama.2016.0291 10.1136/thoraxjnl-2011-201081 10.1097/01.CCM.0000251821.44259.F3 10.1007/s001340050927 10.1186/cc119 |
ContentType | Journal Article |
Copyright | Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. 2020 |
Copyright_xml | – notice: Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. – notice: Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. 2020 |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.5005/jp-journals-10071-G23186 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1998-359X |
EndPage | S81 |
ExternalDocumentID | 10_5005_jp_journals_10071_G23186 32205957 |
Genre | Journal Article |
GroupedDBID | --- 29I 2WC 3V. 53G 5GY 5VS 7X7 8FI 8FJ 8G5 AAWTL ABDBF ABUWG ABXLX ACGFO ACGFS ACIHN ADBBV ADRAZ AEAQA AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC B0M BAWUL BENPR BPHCQ BVXVI C1A CCPQU DIK DU5 DWQXO E3Z EAD EAP EBD EBS EJD EMK EOJEC EPL ESX F5P FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 H13 HMCUK HYE IAO IEA IHE IHR IHW IL9 IOF IPO ITC KQ8 M2O M48 M~E NPM O5R O5S OBODZ OK1 P2P PIMPY PQQKQ PROAC RBI RMW RNS RPM TR2 TUS UKHRP W2D W3E XSB ~8M AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c365t-f33ca71cd5ac7fe45b4fc7d18a1b410f085aeaed0283847a64d9af78dc1fbdb23 |
IEDL.DBID | RPM |
ISSN | 0972-5229 |
IngestDate | Tue Sep 17 21:21:17 EDT 2024 Sat Oct 26 04:28:14 EDT 2024 Fri Aug 23 02:09:21 EDT 2024 Sat Nov 02 11:59:06 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | Suppl 1 |
Keywords | Acute respiratory failure Chronic obstructive pulmonary disease ICU Mechanical ventilation Non invasive ventilation Guidelines |
Language | English |
License | Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c365t-f33ca71cd5ac7fe45b4fc7d18a1b410f085aeaed0283847a64d9af78dc1fbdb23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085817/ |
PMID | 32205957 |
PQID | 2382665234 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7085817 proquest_miscellaneous_2382665234 crossref_primary_10_5005_jp_journals_10071_G23186 pubmed_primary_32205957 |
PublicationCentury | 2000 |
PublicationDate | 2020-Jan 2020-01-01 20200101 |
PublicationDateYYYYMMDD | 2020-01-01 |
PublicationDate_xml | – month: 01 year: 2020 text: 2020-Jan |
PublicationDecade | 2020 |
PublicationPlace | India |
PublicationPlace_xml | – name: India |
PublicationTitle | Indian journal of critical care medicine |
PublicationTitleAlternate | Indian J Crit Care Med |
PublicationYear | 2020 |
Publisher | Jaypee Brothers Medical Publishers |
Publisher_xml | – name: Jaypee Brothers Medical Publishers |
References | ref=63 ref=62 ref=61 ref=60 ref=69 ref=68 ref=67 ref=66 ref=65 ref=64 ref=1 ref=7 ref=6 ref=9 ref=8 ref=3 ref=2 ref=5 ref=4 ref=74 ref=73 ref=72 ref=71 ref=70 ref=109 ref=79 ref=78 ref=77 ref=76 ref=75 ref=102 ref=101 ref=104 ref=103 ref=106 ref=105 ref=108 ref=107 ref=100 ref=41 ref=40 ref=49 ref=48 ref=47 ref=46 ref=45 ref=44 ref=43 ref=42 ref=113 ref=112 ref=115 ref=114 ref=117 ref=116 ref=119 ref=118 ref=111 ref=110 ref=52 ref=51 ref=50 ref=59 ref=58 ref=57 ref=56 ref=55 ref=54 ref=53 ref=124 ref=123 ref=126 ref=125 ref=128 ref=127 ref=129 ref=120 ref=122 ref=121 ref=27 ref=26 ref=25 ref=24 ref=23 ref=22 ref=21 ref=20 ref=135 ref=134 ref=137 ref=136 ref=139 ref=138 ref=29 ref=28 ref=131 ref=130 ref=133 ref=132 ref=30 ref=38 ref=37 ref=36 ref=35 ref=34 ref=33 ref=32 ref=31 ref=146 ref=145 ref=148 ref=147 ref=39 ref=140 ref=142 ref=141 ref=144 ref=143 ref=85 ref=84 ref=83 ref=82 ref=81 ref=80 ref=89 ref=88 ref=87 ref=86 ref=96 ref=95 ref=94 ref=93 ref=92 ref=91 ref=90 ref=16 ref=15 ref=14 ref=13 ref=12 ref=11 ref=99 ref=10 ref=98 ref=97 ref=19 ref=18 ref=17 |
References_xml | – ident: ref=68 doi: 10.1016/j.rmed.2006.03.018 – ident: ref=84 doi: 10.1007/s00134-017-4947-1 – ident: ref=26 doi: 10.1136/bmj.c5462 – ident: ref=78 doi: 10.1136/emj.2004.019786 – ident: ref=116 doi: 10.1164/rccm.200509-1507OC – ident: ref=42 doi: 10.1136/emj.2009.089102 – ident: ref=62 doi: 10.1016/S0140-6736(06)68506-1 – ident: ref=80 doi: 10.1056/NEJM200102153440703 – ident: ref=30 doi: 10.1056/NEJM199509283331301 – ident: ref=17 doi: 10.1136/thorax.55.7.550 – ident: ref=31 doi: 10.1016/j.jcrc.2008.08.007 – ident: ref=92 doi: 10.1097/SLA.0b013e3181675829 – ident: ref=110 doi: 10.1177/1751143715571698 – ident: ref=140 doi: 10.4187/respcare.04619 – ident: ref=104 doi: 10.1097/00000542-199808000-00013 – ident: ref=126 doi: 10.1007/s00134-005-2823-x – ident: ref=58 doi: 10.1016/S0140-6736(00)47948-1 – ident: ref=65 doi: 10.1136/pgmj.2004.031229 – ident: ref=88 doi: 10.1016/S1470-2045(13)70009-3 – ident: ref=4 – ident: ref=14 doi: 10.1086/514711 – ident: ref=106 doi: 10.1001/jama.2015.5213 – ident: ref=72 doi: 10.1097/CCM.0000000000002361 – ident: ref=102 doi: 10.1016/j.soard.2017.02.009 – ident: ref=64 doi: 10.1186/s12873-018-0216-z – ident: ref=13 doi: 10.1186/cc3805 – ident: ref=74 doi: 10.1164/rccm.201606-1306OC – ident: ref=108 doi: 10.1016/j.annfar.2009.04.012 – ident: ref=71 doi: 10.1016/j.jcrc.2015.10.018 – ident: ref=79 doi: 10.1503/cmaj.100071 – ident: ref=89 doi: 10.1097/ALN.0b013e3181c5e5f2 – ident: ref=136 doi: 10.1136/thx.52.3.249 – ident: ref=75 doi: 10.1186/s13054-019-2575-6 – ident: ref=76 doi: 10.1378/chest.09-1114 – ident: ref=121 doi: 10.1378/chest.09-2517 – ident: ref=99 doi: 10.5664/jcsm.6278 – ident: ref=115 doi: 10.5005/jp-journals-10071-23219 – ident: ref=67 doi: 10.1007/s00134-008-0998-7 – ident: ref=144 doi: 10.5152/TurkThoracJ.2017.17036 – ident: ref=101 doi: 10.1007/s11695-011-0381-6 – ident: ref=122 doi: 10.1111/j.1469-0691.2012.03797.x – ident: ref=86 doi: 10.1177/0885066619844713 – ident: ref=16 doi: 10.5005/jp-journals-10071-23101 – ident: ref=138 doi: 10.1183/09031936.01.17202590 – ident: ref=105 doi: 10.1164/ajrccm.164.7.2101089 – ident: ref=45 doi: 10.1164/rccm.201206-1101OC – ident: ref=98 doi: 10.1007/s12630-011-9497-3 – ident: ref=35 doi: 10.1111/j.1742-1241.2002.tb11202.x – ident: ref=7 doi: 10.1007/s00134-015-4087-4 – ident: ref=119 doi: 10.1186/cc8044 – ident: ref=63 doi: 10.1002/14651858.CD005351.pub3 – ident: ref=77 doi: 10.1378/chest.97.4.943 – ident: ref=134 doi: 10.1097/CCM.0000000000002818 – ident: ref=90 doi: 10.1001/jama.2016.2706 – ident: ref=91 doi: 10.1378/chest.128.4.2688 – ident: ref=50 doi: 10.1001/jama.284.18.2361 – ident: ref=85 doi: 10.1186/s13054-016-1586-9 – ident: ref=20 – ident: ref=123 doi: 10.4187/respcare.05481 – ident: ref=125 doi: 10.2169/internalmedicine.49.3749 – ident: ref=109 doi: 10.1378/chest.122.5.1857 – ident: ref=53 – ident: ref=142 doi: 10.1186/1471-2466-13-12 – ident: ref=25 doi: 10.1136/thx.2008.102947 – ident: ref=1 doi: 10.5005/ijccm-17-S1-42 – ident: ref=15 doi: 10.1016/j.rmed.2012.03.009 – ident: ref=19 doi: 10.1136/thx.47.1.34 – ident: ref=36 – ident: ref=39 doi: 10.1164/ajrccm.161.3.9808143 – ident: ref=56 doi: 10.1378/chest.104.3.770 – ident: ref=28 – ident: ref=130 doi: 10.1111/imj.13632 – ident: ref=5 doi: 10.1136/thoraxjnl-2015-208209 – ident: ref=69 doi: 10.1007/978-3-642-11365-9_36 – ident: ref=107 doi: 10.1097/MD.0000000000004734 – ident: ref=61 doi: 10.1001/jama.294.24.3124 – ident: ref=81 doi: 10.1016/j.jcrc.2017.01.007 – ident: ref=49 doi: 10.1001/jama.290.22.2985 – ident: ref=100 doi: 10.1016/j.soard.2008.05.003 – ident: ref=60 doi: 10.1056/NEJMoa0707992 – ident: ref=11 doi: 10.1016/0002-9343(93)90060-3 – ident: ref=95 doi: 10.1007/s11695-009-9928-1 – ident: ref=93 doi: 10.1378/chest.09-0360 – ident: ref=87 doi: 10.1186/s12890-016-0289-y – ident: ref=112 doi: 10.4187/respcare.01775 – ident: ref=9 doi: 10.1164/ajrccm/142.3.523 – ident: ref=51 doi: 10.1378/chest.127.3.952 – ident: ref=43 doi: 10.1183/09031936.02.00287402 – ident: ref=59 doi: 10.1016/j.annemergmed.2006.10.024 – ident: ref=127 doi: 10.1002/14651858.CD004104.pub3 – ident: ref=137 doi: 10.1164/ajrccm.157.1.96-12052 – ident: ref=146 doi: 10.1080/17434440.2016.1218759 – ident: ref=55 – ident: ref=66 doi: 10.1016/j.jjcc.2016.05.015 – ident: ref=103 doi: 10.1053/jcan.2000.9488 – ident: ref=96 doi: 10.1007/s11695-007-9079-1 – ident: ref=48 doi: 10.1136/thx.56.9.708 – ident: ref=147 doi: 10.1164/ajrccm.164.9.2011119 – ident: ref=32 doi: 10.1378/chest.114.6.1636 – ident: ref=41 doi: 10.1016/S0140-6736(00)02323-0 – ident: ref=143 doi: 10.1016/j.jcrc.2016.12.023 – ident: ref=29 doi: 10.1016/0140-6736(93)90696-E – ident: ref=139 doi: 10.1136/thx.2010.142661 – ident: ref=148 – ident: ref=8 – ident: ref=21 doi: 10.1183/09031936.96.09061240 – ident: ref=135 doi: 10.1186/s12890-015-0139-3 – ident: ref=52 doi: 10.1378/chest.116.2.521 – ident: ref=46 doi: 10.2147/COPD.S3454 – ident: ref=113 doi: 10.1007/s00134-011-2375-1 – ident: ref=6 doi: 10.1183/13993003.02426-2016 – ident: ref=97 doi: 10.1590/S1413-35552010005000023 – ident: ref=57 doi: 10.7326/0003-4819-12-6-754 – ident: ref=114 doi: 10.1186/cc10328 – ident: ref=10 – ident: ref=118 doi: 10.1097/ALN.0b013e31821811ba – ident: ref=3 doi: 10.1164/ajrccm.163.1.ats1000 – ident: ref=22 doi: 10.1183/09031936.00.15109800 – ident: ref=34 doi: 10.1016/S0025-7753(03)73798-1 – ident: ref=128 – ident: ref=129 doi: 10.1007/s00134-001-1114-4 – ident: ref=83 doi: 10.1001/jama.2015.12402 – ident: ref=94 doi: 10.1177/000313480807400914 – ident: ref=27 doi: 10.1136/thx.51.10.1048 – ident: ref=82 doi: 10.1186/s13054-018-2079-9 – ident: ref=24 – ident: ref=18 doi: 10.1136/thx.2010.153114 – ident: ref=38 doi: 10.1164/ajrccm.151.6.7767523 – ident: ref=70 doi: 10.1186/cc13103 – ident: ref=37 doi: 10.4103/0970-2113.68308 – ident: ref=111 doi: 10.1016/j.transproceed.2009.02.048 – ident: ref=133 doi: 10.1097/CCM.0000000000001379 – ident: ref=47 doi: 10.7326/0003-4819-138-11-200306030-00007 – ident: ref=132 doi: 10.4187/respcare.05481 – ident: ref=120 doi: 10.1001/jama.2009.1496 – ident: ref=33 doi: 10.1007/s00134-002-1478-0 – ident: ref=2 doi: 10.1136/thorax.57.3.192 – ident: ref=54 doi: 10.1007/BF02968110 – ident: ref=117 doi: 10.1007/s00134-009-1717-8 – ident: ref=44 doi: 10.1002/14651858.CD004104.pub4 – ident: ref=23 doi: 10.1378/chest.113.5.1339 – ident: ref=124 doi: 10.1016/j.medine.2019.11.007 – ident: ref=40 doi: 10.1093/ageing/afr003 – ident: ref=73 doi: 10.1001/jama.2016.0291 – ident: ref=145 doi: 10.1136/thoraxjnl-2011-201081 – ident: ref=131 doi: 10.1097/01.CCM.0000251821.44259.F3 – ident: ref=141 doi: 10.1007/s001340050927 – ident: ref=12 doi: 10.1186/cc119 |
SSID | ssj0026921 |
Score | 2.4569685 |
Snippet | A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | S61 |
SubjectTerms | Guidelines/Position Statements |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB6VIkW9VDwKpDxkJK5O613v2ntCVUSaIqUHYKvcVn6KVNUmNElV_j0zu9nQUsSBs9eWPDPWfLPz-TPAh-C8t9obHpXRXIZUcELVHHOpzYLRRjeKN5PzfFzKz9NsugPddcWNAZd_Le3oPany-mpw--PnRzzwiF8HGQbR0eWCd_M4Nf0FP0XUovNH8DiRWK8ToU9uewtJXjS3sUi3BsuwpGj5Pf9caQ96Kd1ILSiL3c1fD0Dpn9zKO8lq9AT2NyiTnbRh8RR2Qv0MepNNH_05uLOvw-GEna5J5IqI7wyxK0MsyMplYPPIzuc1n9U3hsjt7IIYRS1njs1qduLWq8C-_O7Rs5GZEbu9GSQ9D3Y2LJcHUI4-fRuO-ea5Be7SPFvxmKbOKOF8ZpyKQWZWRqe80EZYKY4jgjMTTPCESDCnmVz6wkSlvRPRepukL2C3ntfhFTAncf_OOaVdLnUS7HEaY1JEpXxmbSr6IDojVotWVaPCaoR8UF0uqs4HjaCyqFof9OF9Z-0KjwD1NUwd5utlhagDYQZW1LIPL1vrb1ft3NYHdc8v2w9IXvv-SD373shsK9ywFurwv2e-hr2EqvPmh80b2F1dr8NbhDAr-66JyF86EvNB priority: 102 providerName: Scholars Portal |
Title | ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32205957 https://www.proquest.com/docview/2382665234 https://pubmed.ncbi.nlm.nih.gov/PMC7085817 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCaaHoZdhu6dPQoN2FVNZcuWfCyMJe0AF8O2DLkZemIuWiVYkv7-UbLdtdttF19kGTZJgB_Nj58APjpjrZZWUS-UpNzljEZUTTGX6sIpqWRSvGkuy_Ml_7wqVgdQjLMwibRvdHcSrm9OQvczcSs3N2Y28sRmX5paIE6QTMwmMMEAHUv0ocoqqzRsFWVpsMrKqp6-U2C0za42dPDQlkZ2AKMLhDcyHmOUx4HTKiap--npH8z5N3XyXi6aH8GTAUSSs_5ln8KBC8_gUTO0yZ-DufhW1w1Z7KOGVeS1E4SmBKEeWW4dWXtyuQ60C7cqctfJj0gY6ilxpAvkzOx3jnz904Inc9VF8npajHId5KJebl_Acv7pe31Oh9MUqMnLYkd9nhslmLGFMsI7XmjujbBMKqY5O_VoU-WUsxFwYMpSJbeV8kJaw7y2OstfwmFYB_caiOH4_cYYIU3JZeb0ae59VnkhbKF1zqbARiO2m140o8ViI_qgvdq0ow-SXjJrex9M4cNo7RYjPLYtVHDr_bZFUIEoAgtmPoVXvfXvnjq6bQrigV_ubojq2Q9XMKiSivYQRG_-e-dbeJzF4jv9j3kHh7tfe_ceEcpOH8NksWJ4bbg8TtH5GzO-6jw |
link.rule.ids | 230,315,730,783,787,888,2228,24330,27936,27937,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VIgGXlm-WTyNx9e46cWLnWEXd7kKzQtCteov8KVJodsUmPfDrsZ2ktOUE50ksOc_WvInfPAN8MEprybXAlgmOqYkJ9qwau1wqEyO44MHxplim8xX9eJac7UAy9MIE0b6S1bj-cTGuq29BW7m5UJNBJzb5XOTM8QRO2OQO3HX7dUqHIr2vs9IstFt5YxpXZ0VZJ-BJ3HqbnG9wj9EWe30AwUeO4HB_kVHsW04zn6auJ6i_WOdt8eS1bDTbh9NhHp0I5fu4beRY_bpl8fjPE30Iez0_RQdd-BHsmPox3Cv6E_gnoBZf87xAR623x_KSeeRYL3IsEq22Bq0tWq5rXNWXwsvi0anXInVqO1TV6EC1jUFf_pzuo5movC4-BL0TCFrkq-1TWM0OT_I57i9qwCpOkwbbOFaCEaUToZg1NJHUKqYJF0RSMrVuFsIIoz2XcdlQpFRnwjKuFbFSyyh-Brv1ujYvACnqPqxSinGVUh4ZOY2tjTLLmE6kjMkIyIBOuen8OEpXx3hwy_NNOYAbrJhJ2YE7gvcDjKXbPP5ERNRm3W5Lx1ccQXG1OB3B8w7Wq1GH9TACdgPwqwe8MffNiIMxGHT3sL387zffwf35SXFcHi-Wn17Bg8jX-OG3z2vYbX625o0jQo18G5b9bx_8Cno |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB1BkSoufFOWTyNx9WadOLFzrALbLrCrClhUcYn8KVJoNmITDvx6bCcp23Lr2U4k59maN5nnNwBvjNJaci2wZYJjahKCPavGLpbK1AgueHC8Wa6y4zV9f5qe7rT6CqJ9Jatp_fN8Wlffg7ayOVfRqBOLTpYFczyBExY12kY34ZY7s7NsTNSHXCvLw5Urb07jcq0470U8qdtz0VmDB5y22GsECD5yJIf7ZkaJv3aa-1C1G6T-Y55XBZQ7EWl-F76Na-mFKD-mXSun6s8Vm8drLfYe3Bl4Kjrsp9yHG6Z-APvLoRL_ENTic1Es0VHnbbK8dB459oscm0TrrUEbi1abGlf1b-Hl8eir1yT1qjtU1ehQda1Bn_5V-dFcVF4fHwa9IwhaFOvtI1jP330pjvHQsAGrJEtbbJNECUaUToVi1tBUUquYJlwQScnMupUII4z2nMZFRZFRnQvLuFbESi3j5DHs1ZvaPAGkqPu4SinGVUZ5bOQssTbOLWM6lTIhEyAjQmXT-3KULp_xAJdnTTkCHCyZSdkDPIHXI5SlO0S-MiJqs-m2peMtjqi4nJxO4KCH9uKt456YALsE-sUEb9B9ecRBGYy6B-ieXvvJV7B_8nZeflysPjyD27FP9cPfn-ew1_7qzAvHh1r5Muz8v2sCDPo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ISCCM+Guidelines+for+the+Use+of+Non-invasive+Ventilation+in+Acute+Respiratory+Failure+in+Adult+ICUs&rft.jtitle=Indian+journal+of+critical+care+medicine&rft.au=Chawla%2C+Rajesh&rft.au=Dixit%2C+Subhal+B&rft.au=Zirpe%2C+Kapil+Gangadhar&rft.au=Chaudhry%2C+Dhruva&rft.date=2020-01-01&rft.pub=Jaypee+Brothers+Medical+Publishers&rft.issn=0972-5229&rft.eissn=1998-359X&rft.volume=24&rft.issue=Suppl+1&rft.spage=S61&rft.epage=S81&rft_id=info:doi/10.5005%2Fjp-journals-10071-G23186&rft_id=info%3Apmid%2F32205957&rft.externalDBID=PMC7085817 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0972-5229&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0972-5229&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0972-5229&client=summon |